Loading stock data…
NVCR
$16.84+0.22 (+1.32%)
Market OpenUpdated 2:17 PM EDT
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NovoCure Limited in the Healthcare sector is trading at $17.02. The stock is currently 15% below its 52-week high of $20.06, remaining 35.5% above its 200-day moving average. Technical signals show overbought RSI of 81 and bullish MACD crossover, explaining why NVCR maintains its current momentum and trend strength. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 81) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$16.84
Potential Upside
5%
Whystock Fair Value$17.68
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus7 analysts
Buy
Mean target$25.79+53.1%
Range$13.50 – $48.00
Fundamentals
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.51B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-50.21%
Volume
Today's trading volume
1.82M
Recent News
International Markets and NovoCure (NVCR): A Deep Dive for Investors
Review NovoCure's (NVCR) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 33% over the past week following NovoCure Limited 's ( NASDAQ:NVCR...
NovoCure Limited Q1 2026 Earnings Call Summary
Moby summary of NovoCure Limited's Q1 2026 earnings call
NovoCure (NVCR) Q1 2026 Earnings Transcript
Adam Daney: Good morning, and thank you for joining us to review NovoCure's First Quarter 2026 financial performance. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements.
Two Medical Stocks Skyrocket After Demolishing Views — And One Is About To Break Out
Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.